Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.
about
Genetics of cardiovascular and renal complications in diabetesAPOL1 toxin, innate immunity, and kidney injuryInsights into kidney diseases from genome-wide association studies.Social Determinants of Racial Disparities in CKD.ASN Presidential Address 2014: moving past nephrology's midlife crisisShould kidney donors be genotyped for APOL1 risk alleles?African origins and chronic kidney disease susceptibility in the human immunodeficiency virus era.Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesRe-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South AfricansExamination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.APOL1 Risk Alleles are Associated with More Severe Arteriosclerosis in Renal Resistance Vessels with Aging and Hypertension.APOL1 nephropathy: from gene to mechanisms of kidney injury.Hypertension-attributed nephropathy: what's in a name?Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy.APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.An investigation of APOL1 risk genotypes and preterm birth in African American population cohorts.Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK.Race, APOL1 Risk, and eGFR Decline in the General Population.APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial.Hemostatic Factors, APOL1, and ESRD Risk: Another Piece of the Puzzle?Apolipoprotein L1-associated nephropathy and the future of renal diagnostics.The Role of Ethnic Variation and CKD.APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.Apolipoprotein L1 Gene Effects on Kidney Transplantation.APOL1 Risk Variants Independently Associated With Early Cardiovascular Disease Death.High-Density Lipoprotein in Chronic Kidney Diseases-The Devil Is in the Detail.Nephrotic Syndrome Post-Kidney Transplant.Blocking the 5' splice site of exon 4 by a morpholino oligomer triggers APOL1 protein isoform switch.
P2860
Q26752749-279863FA-BA73-4791-B096-AB5D460ECE8BQ28085667-D0482B66-39D2-4D59-9FDB-8A5ACB1054BCQ30248678-DFCD0B26-0B11-4CE8-8E15-765CD8339108Q30250319-C3321D07-584C-4051-87B1-F19CCCFB665AQ35228574-F7FDF8C1-D4EF-4A38-A822-313935A9F440Q35246302-F309A40C-14C9-4F16-8DCC-ED6A05B64022Q35567885-280000AE-C721-4AB0-901A-22CA1D6BEF60Q35576129-DB647929-6D1C-469F-B553-435446C7D9F6Q35686453-824212E2-DA8A-4FEB-9ADE-F63254A32805Q36109136-C8C7559F-84E2-4635-83F0-B588318B63DAQ36223249-8D25A513-D681-4DE8-885D-726B8BDFD742Q36349456-6FE705B5-5A9F-4C90-BB82-B4BE2BE07AF0Q36385113-7CC979FB-621C-47D8-A6F1-F40CFB62BC57Q37234093-A9948AC8-A118-4B84-826D-C4CAA9CD81EBQ38308481-131D2097-2DC6-4001-B593-D5E27072ACF0Q38629320-692615C4-8CE2-465E-A5CC-C084F0A9755FQ38682842-04B5829D-FDBF-469D-993D-529495865988Q38878740-BB69FF81-7D07-42BB-AEAD-C88016A1C993Q39112267-932F5198-A30D-4B69-81F3-BB2CAC88EF34Q39207538-BE7F084E-10EF-43D4-BBF0-283FDE19E8FEQ39379366-814C6DC7-7A19-49AA-A453-6DB86A993467Q40733337-F7FAA16C-3B0C-42E2-99B3-6AA132CF35EBQ40860089-E79271C7-F6D4-4A64-90B7-EB8C67F05414Q41129046-684B4F0C-E006-4CE1-A0F5-2D9CBFFEE943Q42569055-FEA63AE2-8488-40F5-9CB4-07F43BE21F34Q42943112-437BF0E3-18C1-4972-A8A7-05736D33C9B4Q43232843-A3BA812D-33E0-449B-BE59-755FD1FBB878Q46457437-5BDB3E01-C703-4248-A08A-26BCF6511904Q47644189-C2C00BDF-ECEB-4974-A941-F8D9ACD2DB07Q49409572-EDFEFFD9-160D-4BEF-877C-2F8D2B369B82Q52374541-FF13631A-463D-4C9B-B175-3671872D337DQ53730009-097E5772-2DFA-4306-A904-0ECD5B7509F9Q55247200-25F8386B-7DBD-4B92-B24B-2435065BFDD4
P2860
Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@ast
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@en
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@nl
type
label
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@ast
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@en
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@nl
prefLabel
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@ast
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@en
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@nl
P2860
P356
P1476
Gene-gene and gene-environment ...... 1 gene-associated nephropathy.
@en
P2093
Barry I Freedman
Karl Skorecki
P2860
P304
P356
10.2215/CJN.01330214
P577
2014-06-05T00:00:00Z